Investor deep dive
SkinBioTherapeutics’ new boss has big plans for SkinBiotix
SkinBioTherapeutics 'getting more confident' as it hits half-way point in human studies
Dr Cath O'Neill, chief executive of SkinBioTherapeutics PLC (AIM:SBTX), tells Proactive London's Andrew Scott there've been no safety or compliance concerns with people taking part in a test of the company’s skin cream.
Half the 120 volunteers have been through the trial process with the study set to complete as expected during this quarter.
Data yielded will be assessed to determine the effectiveness of the group’s SkinBiotix technology and whether it retains the same beneficial property of improving skin health when in a cream formulation.
Quick facts: SkinBioTherapeutics PLC